Your browser doesn't support javascript.
Ultrasensitive, high-throughput, and rapid simultaneous detection of SARS-CoV-2 antigens and IgG/IgM antibodies within 10 min through an immunoassay biochip.
Wang, Chunhua; Wang, Chao; Qiu, Jiaoyan; Gao, Jianwei; Liu, Hong; Zhang, Yu; Han, Lin.
  • Wang C; Institute of Marine Science and Technology, Shandong University, Qingdao, 266000, China.
  • Wang C; Institute of Marine Science and Technology, Shandong University, Qingdao, 266000, China.
  • Qiu J; Institute of Marine Science and Technology, Shandong University, Qingdao, 266000, China.
  • Gao J; Institute of Marine Science and Technology, Shandong University, Qingdao, 266000, China.
  • Liu H; Institute of Crystal Materials, Shandong University, Jinan, 250100, Shandong, China.
  • Zhang Y; Institute of Marine Science and Technology, Shandong University, Qingdao, 266000, China. yuzhang@sdu.edu.cn.
  • Han L; Institute of Marine Science and Technology, Shandong University, Qingdao, 266000, China. hanlin@sdu.edu.cn.
Mikrochim Acta ; 188(8): 262, 2021 07 20.
Article in English | MEDLINE | ID: covidwho-1317559
ABSTRACT
COVID-19 is now a severe threat to global health. Facing this pandemic, we developed a space-encoding microfluidic biochip for high-throughput, rapid, sensitive, simultaneous quantitative detection of SARS-CoV-2 antigen proteins and IgG/IgM antibodies in serum. The proposed immunoassay biochip integrates the advantages of graphene oxide quantum dots (GOQDs) and microfluidic chip and is capable of conducting multiple SARS-CoV-2 antigens or IgG/IgM antibodies of 60 serum samples simultaneously with only 2 µL sample volume of each patient. Fluorescence intensity of antigens and IgG antibody detection at emission wavelength of ~680 nm was used to quantify the target concentration at excitation wavelength of 632 nm, and emission wavelength of ~519 nm was used during the detection of IgM antibodies at excitation wavelength of 488 nm. The method developed has a large linear quantification detection regime of 5 orders of magnitude, an ultralow detection limit of ~0.3 pg/mL under optimized conditions, and less than 10-min qualitative detection time. The proposed biosensing platform will not only greatly facilitate the rapid diagnosis of COVID-19 patients, but also provide a valuable screening approach for infected patients, medical therapy, and vaccine recipients.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin G / Immunoglobulin M / Immunoassay / SARS-CoV-2 / Antigens, Viral Type of study: Diagnostic study / Qualitative research Topics: Vaccines Limits: Humans Language: English Journal: Mikrochim Acta Year: 2021 Document Type: Article Affiliation country: S00604-021-04896-w

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunoglobulin G / Immunoglobulin M / Immunoassay / SARS-CoV-2 / Antigens, Viral Type of study: Diagnostic study / Qualitative research Topics: Vaccines Limits: Humans Language: English Journal: Mikrochim Acta Year: 2021 Document Type: Article Affiliation country: S00604-021-04896-w